

Zilovertamab vedotin

Cat. No.:	HY-P99956
Target:	Antibody-Drug Conjugates (ADCs); Apoptosis
Pathway:	Antibody-drug Conjugate/ADC Related; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody-agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer ^[1] .								
In Vitro	Zilovertamab vedotin (VLS-101; 0-100 µg/mL) induces cytotoxicity in ROR1 ⁺ primary MCL cells in a dose-dependent manner ^[1] . Zilovertamab vedotin (24h; ibrutinib-sensitive (JeKo-1) and resistant (JeKo BTK KD_2) cell lines) induces cell apoptosis and cell cycle arrest at G2/M ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	Zilovertamab vedotin (VLS-101; 2.5 mg/kg; i.v.; weekly, for 3 weeks) targets ROR1-expressing PDX models with dual resistance to ibrutinib and CAR T. A PDX model. Zilovertamab vedotin inhibits tumor growth ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>NSG PDX mice models with dual resistance to ibrutinib and CAR T. A PDX model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>intravenous injection; weekly, for 3 weeks</td> </tr> <tr> <td>Result:</td> <td>Eliminated subcutaneous tumor growth of BA-resistant PDX model (PDX-1). Prolonged tumor bearing mouse survival.</td> </tr> </table>	Animal Model:	NSG PDX mice models with dual resistance to ibrutinib and CAR T. A PDX model ^[1]	Dosage:	2.5 mg/kg	Administration:	intravenous injection; weekly, for 3 weeks	Result:	Eliminated subcutaneous tumor growth of BA-resistant PDX model (PDX-1). Prolonged tumor bearing mouse survival.
Animal Model:	NSG PDX mice models with dual resistance to ibrutinib and CAR T. A PDX model ^[1]								
Dosage:	2.5 mg/kg								
Administration:	intravenous injection; weekly, for 3 weeks								
Result:	Eliminated subcutaneous tumor growth of BA-resistant PDX model (PDX-1). Prolonged tumor bearing mouse survival.								

REFERENCES

[1]. Jiang VC, et, al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021 Aug 28;14(1):132.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA